Ten of the 12 lectins (except for peanut lectin and MAL) we tested showed inhibitory effect on SARS-CoV-2 pseudovirus (original strain) infection, next we evaluated their antiviral activity against a panel of mutant strains and variants using a pseudovirus-based neutralization assay, including the artificial mutants at N-/O-linked glycosylation site, natural existed amino acid mutants which had an impact on antigenicity or showed increased mutation frequency, as well as the concerned variants B.1.1.7, B.1.351, and P.1. This evidence concerns the gene MAL and infection.